Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options
Current Oncology · 07.03.2023 · 30 (3) · 3160-3175
DOI: 10.3390/curroncol30030239 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 07.03.2023. Verfasst von Francesco Petrella und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, European Institute of Oncology IRCCS, 20141 Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung cancer is the second-most commonly diagnosed cancer and the leading cause of cancer death worldwide. The most common histological type is non-small-cell lung cancer, accounting for 85% of all lung cancer cases. About one out of three new cases of non-small-cell lung cancer are diagnosed at a locally advanced stage—mainly stage III—consisting of a widely heterogeneous group of patients presenting significant differences in terms of tumor volume, local diffusion, and lymph nodal involvement. Stage III NSCLC therapy is based on the pivotal role of multimodal treatment, including surgery, radiotherapy, and a wide-ranging option of systemic treatments. Radical surgery is indicated in the case of hilar lymphnodal involvement or single station mediastinal ipsilateral involvement, possibly after neoadjuvant chemotherapy; the best appropriate treatment for multistation mediastinal lymph node involvement still represents a matter of debate. Although the main scope of treatments in this setting is potentially curative, the overall survival rates are still poor, ranging from 36% to 26% and 13% in stages IIIA, IIIB, and IIIC, respectively. The aim of this article is to provide an up-to-date, comprehensive overview of the state-of-the-art treatments for stage III non-small-cell lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, European Institute of Oncology IRCCS, 20141 Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy.
- Service of Radiology, Imaging Institute of Southern Switzerland (IIMSI), EOC, Via Tesserete 46, 6900 Lugano, Switzerland.
- Faculty of Biomedical Sciences, University of Italian Switzerland, Via Buffi 13, 6900 Lugano, Switzerland.
- Division of Thoracic Oncology, European Institute of Oncology IRCCS, 20141 Milan, Italy.
- Radiation Oncology, Oncological Institute of Southern Switzerland, EOC, 6500 Bellinzona, Switzerland.
ORCID-Profile: Francesco Petrella, Stefania Rizzo, Ilaria Attili, Antonio Passaro, Filippo Del Grande, Monica Casiraghi
Zitieren
APA
Petrella, F., Rizzo, S., Attili, I., Passaro, A., Zilli, T., Martucci, F., Bonomo, L., Del Grande, F., Casiraghi, M., De Marinis, F., & Spaggiari, L. (2023). Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options. Current Oncology, 30(3), 3160-3175. https://doi.org/10.3390/curroncol30030239
Vancouver
Petrella F, Rizzo S, Attili I, Passaro A, Zilli T, Martucci F, et al. Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options. Current Oncology. 2023;30(3):3160-3175. doi:10.3390/curroncol30030239
BibTeX
@article{Petrella2023,
author = {Petrella, Francesco and Rizzo, Stefania and Attili, Ilaria and Passaro, Antonio and Zilli, Thomas and Martucci, Francesco and Bonomo, Luca and Del Grande, Filippo and Casiraghi, Monica and De Marinis, Filippo and Spaggiari, Lorenzo},
title = {Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options},
journal = {Current Oncology},
year = {2023},
volume = {30},
number = {3},
pages = {3160--3175},
doi = {10.3390/curroncol30030239}
}
EUVIMED